Vertex Pharmaceuticals (VRTX -12.3%) slides on weaker-than-expected Q3 results and a downgrade...

|About: Vertex Pharmaceuticals Inco... (VRTX)|By:, SA News Editor

Vertex Pharmaceuticals (VRTX -12.3%) slides on weaker-than-expected Q3 results and a downgrade to Neutral by Goldman. Citing the weak results and the recent NACFC conference, Goldman says it's formed a more cautious outlook on the company's key pipeline program, and sees a limited number of upside catalysts heading into 2013.